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Abstract

Weight-loss medications are currently recommended for use
only as an adjunct to diet, exercise, and behavior modifica
tion. Little, however, is known about the benefits of com
bining behavioral and pharmacological therapies or about
the mechanisms that would make these combined ap
proaches more effective than either used alone. This article
reviews the effects of adding pharmacotherapy (i.e., princi
pally sibutramine and orlistat) to a modest program of
lifestyle modification. Studies revealed that the addition of
medication typically improved short- and long-term weight
loss compared with lifestyle modification alone. The best
results, however, were obtained when medications were
combined with an intensive, group program of lifestyle
modification. The two approaches may have additive
effects; behavioral treatment seems to help obese individu
als control the external (i.e., food-related) environment,
whereas pharmacotherapy may control the internal environ
ment by reducing hunger, cravings, or nutrient absorption.
The article examines possible methods of sequencing be
havioral and pharmacological therapies and offers sugges
tions for future research.
Key words: weight-loss medications, sibutramine,
orlistat, behavior therapy, obesity

Introduction
The Food and Drug Administration (FDA), as well as an
expert panel convened by the National Heart Lung and
Blood Institute, has recommended that weight-loss medica
tions be used only as an adjunct to a comprehensive pro
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gram of lifestyle modification that includes diet, physical
activity, and behavior therapy (1). A common hypothesis is
that medication should help facilitate adherence to lifestyle
modification. By reducing appetite or nutrient absorption,
medications may make it easier for patients to adhere to a
low-calorie diet. Surprisingly little, however, is known
about the specific benefits of combining these therapies, or
how and when they should be combined. This paper reviews
evidence from randomized control trials that compare the
effects of lifestyle modification, pharmacotherapy, and their
combination. The potential mechanisms of action of com
bination therapy are explored, and ways to maximize the
benefits of this approach are discussed.

Lifestyle Modification
Lifestyle modification generally consists of a combina
tion of dietary modification, exercise, and behavior therapy.
Women who wish to lose weight are usually encouraged to
eat 1200 to 1500 kcal/d and men are encouraged to eat 1500
to 1800 kcal/d. Instruction is provided in consuming a
well-balanced, low-fat diet, as suggested by the Food Guide
Pyramid (2). In addition, patients may be instructed to select
foods high in fiber to enhance satiety and nutrition. They are
also encouraged to gradually increase their physical activity
to 30 min/d, most days of the week (3). Adherence to diet
and exercise recommendations is promoted through the use
of behavioral techniques (4), including recording caloric
intake and physical activity and limiting the places and
activities associated with eating and inactivity (i.e., stimulus
control). Instruction is also provided in cognitive restruc
turing to prevent relapse. Adherence to these weight-control
behaviors may be facilitated by the use of reinforcement
contingencies (e.g., monetary or social support) (5).
Weight Loss
Comprehensive behavioral programs, providing weekly
group treatment of 20 to 26 weeks, produce mean losses of
8 to 10 kg (�9% of initial body weight) and are associated
with attrition of �15% to 20%. By contrast, less intensive
interventions that provide patients with treatment manuals
and minimal or no therapist contact produce weight losses
of only 1 to 5 kg over 6 months (6 – 8).

The well-documented problem with lifestyle modifica
tion is weight regain after treatment termination. On aver
age, in the year after treatment, patients regain �30% to
35% of their weight loss. Approximately 3 to 5 years after
therapy, 50% or more of participants have returned to their
baseline weight (9,10). These results are not entirely dis
couraging considering that most obese people, left untreated
for 3 to 5 years, would probably gain 0.5 to 1 kg per
year (11).
Mechanisms of Action
Reducing energy intake is the key to short-term weight
loss; the greater the energy deficit, the greater the loss
(12,13). Attending treatment sessions and keeping food
records are consistently related to weight loss (1,5– 6), prob
ably because they facilitate adherence to energy restriction.
Whereas increased physical activity may contribute mod
estly to short-term weight loss (14), the role of other
components of lifestyle modification, including stimulus
control, problem-solving, cognitive-restructuring, and rein
forcement contingencies, is unclear. During treatment, cog
nitive restraint (i.e., cognitive control of eating) and selfefficacy increase; however, these variables are only
modestly correlated with weight loss (15,16).
The maintenance of weight loss is facilitated by patients
engaging in high levels of physical activity (17–22). Fre
quent patient-provider contact also prevents weight regain
(23–26). Behavioral-maintenance therapy, however, seems
only to delay rather than to prevent weight regain. Atten
dance of maintenance sessions declines over time, and once
treatment is terminated, patients regain weight (23). As
others have suggested (27), it may be asking too much for
overweight individuals to exert continuous control in the
face of unremitting biological factors and an environment
that supplies an abundance of ready-made high-calorie,
high-fat foods, as well as a multitude of energy-saving
devices. Interventions are needed that make the day-to-day
work of weight control easier and more sustainable. Phar
macotherapy may be helpful in this regard.

Pharmacotherapy
Historically, anorectic agents have induced weight loss
by influencing central nervous system (CNS) receptors as
sociated with eating and appetite regulation. Noradrenergic
(e.g., amphetamines) and serotonergic (e.g., fenfluramines)
agents, for example, were associated with reports of de
creased hunger and increased satiety, respectively (28).
Studies also reported macronutrient-specific effects of CNS
agents (29–31), although the data were contradictory (32–34).
The history of weight-loss agents has been marked by
several adverse experiences. In 1997, for example, fenflu
ramine and dexfenfluramine were withdrawn from the mar
ket because of their association with valvular heart disease

(35). Two medications, sibutramine and orlistat, are cur
rently approved by the FDA for long-term use in obesity
management. Sibutramine is a CNS agent that inhibits the
reuptake of norepinephrine and serotonin. By contrast, orl
istat is a gastric and pancreatic lipase inhibitor that works by
blocking the absorption of about one-third of the fat con
tained in a meal; the undigested fat is excreted in stool (36)
The medications seem to be generally safe and effective
when used with appropriate persons under medical super
vision. The clinical use of these medications has been de
scribed by several investigators (28,37,38).
Sibutramine
Weight Loss. Sibutramine, in conjunction with dietary
therapy, induces weight losses of 4% to 12% of initial body
weight, which are 3 to 9 percentage points greater than those
produced by placebo. Losses have been sustained for up to
2 years with continuous therapy (39,40). Sibutramine has
also been found to induce weight loss independent of sub
jects’ efforts to diet and lose weight (41).
Mechanisms of Action. Sibutramine has been shown to
reduce energy intake, particularly at lunchtime (42). This
may be because peak plasma concentration occurred at this
time, after early morning dosing (41,42). Preliminary re
search did not find that the medication altered macronutrient
selection (41,42); however, further studies are needed. Re
search on the appetite-altering effects of sibutramine has
yielded mixed findings; 6-month studies showed reductions
in hunger and increases in fullness (43,44), but shorter-term
studies found no such effect (45– 48). Studies also were
divided concerning whether the medication has a thermo
genic effect (47,48); it seems to be very weak, if present.
Orlistat
Weight Loss. Orlistat, in conjunction with a reducedcalorie diet, produces weight losses of 5% to 13% of initial
body weight. These losses are 2 to 6 percentage points
greater than those associated with placebo. Weight losses
are generally well-maintained for up to 2 years, although
modest weight regain was observed in patients while they
remained on medication (49,50).
Mechanisms of Action. Unlike sibutramine, orlistat does
not affect the CNS and is unlikely to have a direct effect on
appetite (51). It induces weight loss principally by blocking
the absorption of about one-third of the fat consumed in a
meal. However, orlistat also could affect food preference
through aversive conditioning. Specifically, individuals
may learn to eat less fat to avoid aversive gastrointestinal
side-effects that include increased defecation, soft stools,
fatty/oily evacuation, and oily spotting (50,52,53). In anec
dotal reports, patients noted that orlistat acted as a “watch
dog” for dietary compliance (54). Consistent with this hy
pothesis, one report (55) found that fat intake was generally
higher in the placebo group than in orlistat-treated partici

pants, but differences between groups were not statistically
significant. Another study found similar fat intake in placeboand orlistat-treated groups (52). Thus, further research is
needed to determine orlistat’s effects on food preferences.

Why Is Medication Recommended Only as
an Adjunct to Diet, Exercise, and
Behavior Therapy?
There are several reasons for recommending that phar
macotherapy be added to a program of lifestyle modifica
tion. First, growing evidence shows that a program of mod
est physical activity can reduce the risk of cardiovascular
disease, independent of weight status (56,57). Similarly,
behavioral treatment encourages patients to eat a low-fat,
low-cholesterol diet, which, by itself, may reduce the risk of
coronary artery disease (58). These important benefits would
be lost if weight loss were induced by medication alone.
Second, without lifestyle modification, pharmacotherapy
alone might result in suboptimal short- and long-term
weight losses. Larger weight losses are desirable because
they are generally associated with greater improvements in
weight-related health complications (59). They are also
eagerly desired by obese individuals (60).
Third, adding pharmacotherapy to lifestyle modification
fits well with a stepped-care approach in which the least
aggressive intervention is tried first and, if unsuccessful, is
augmented by more aggressive interventions. In this model,
lifestyle modification is the cornerstone of weight manage
ment, in part, because it is less expensive and has fewer
side-effects than pharmacotherapy. The next section re
views research on the effects of adding pharmacotherapy to
lifestyle modification.

Does the Addition of Pharmacotherapy
Improve the Results of Lifestyle
Modification?
Most studies of pharmacotherapy compare the effects of
placebo plus lifestyle modification with medication plus the
same program of lifestyle modification. These placebo-drug
studies appropriately test the efficacy of the medication. The
use, however, of placebos in these trials limits their assess
ment of lifestyle modification as delivered in clinical prac
tice. A placebo could diminish the effectiveness of the
lifestyle-modification program by reducing participants’ in
volvement in behavioral treatment (61). Nonetheless, the
placebo-controlled trials reviewed below do provide an as
sessment of whether adding medication generally improves
on the results of diet and exercise modification.
Tables 1 and 2 summarize the results of double-blind
placebo controlled trials of 6 months or more that used
sibutramine or orlistat. Participants were overweight or
obese (i.e., body mass index � 25 kg/m2) adults and were

predominantly women. Most trials included relatively weak
programs of lifestyle modification, in part, to better reveal
the effects of the medications (28). Diet and exercise mod
ification was typically initiated during a 2- to 4-week singleblind run-in period, after which subjects were randomized
into the double-blind phase of the study. The diets generally
contained 30% fat and were designed to produce a mild
hypocaloric deficit of 500 to 600 kcal/d. Unless otherwise
noted, data in the tables reflect weight change beginning
after the run-in period. Data from subjects who completed
the trials are reported, unless otherwise noted in the text.
Induction of Weight Loss
As indicated in Table 1, sibutramine produced mean
weight losses that were 3 to 9 kg greater than placebo when
both interventions were combined with a low-intensity pro
gram of lifestyle modification. These findings demonstrate
sibutramine’s efficacy and suggest that the medication can
improve a modest program of lifestyle modification admin
istered with a placebo.
Studies of orlistat plus lifestyle modification produced
weight losses that were 2 to 6 kg greater than those resulting
from placebo plus lifestyle change (Table 2). Thus, similar
to sibutramine, orlistat seems to improve results produced
by minimal lifestyle modification therapy (with placebo).
Whether these medications would have the same weightloss enhancing effect when combined with a more compre
hensive lifestyle-intervention program is unknown. Com
prehensive lifestyle-modification programs provide weekly
group treatment and specific instruction in diet, exercise,
and behavioral strategies. By contrast, the low-intensity
interventions used in most of the studies of sibutramine and
orlistat provided little (e.g., monthly) or no contact with a
weight-loss practitioner and only general recommendations
for modifying eating and exercise habits. Three studies of
fenfluramine (62– 64), as well as one of the fenfluramine
phentermine combination (65) (summarized in Table 3),
found that medication, combined with a comprehensive
program of lifestyle modification, produced significantly
greater weight loss than the same behavioral program used
alone or combined with placebo. However, the potential
benefits of adding medication to a comprehensive lifestylemodification program cannot be fully determined until such
studies are conducted with medications approved for longterm use. In addition, comparison conditions are required,
including lifestyle modification without a placebo pill (66).
Weight-Loss Maintenance
Pharmacotherapy’s greatest benefit may be in facilitating
the long-term maintenance of weight loss. Placebo-con
trolled trials of this issue generally provided the same fre
quency of follow-up visits as used in behavioral treatment
(i.e., monthly or quarterly follow-up visits). In this way, the

Table 1. Randomized double-blind controlled trials of sibutramine and lifestyle modification for obesity

Reference
Apfelbaum et al. (67)

Bray et al. (76)

Bray et al. (77)

Cuellar et al. (43)

Dujovne et al. (94)

Fanghanel et al. (44)

Fujioka et al. (95)

Randomized/
completed
Dose
(n)
(mg/QD)
81/54
78/45
173/147

SIB 10
PL
15
20

6-Month
weight loss
(kg)

1-Year
weight loss
(kg)

�12.7a*
� 9.0b*

�12.7 (12%)a*
�7.6 (7%)b

—

—

—

3 in 6 months; total, 5
over 1 year; dietitian
provided advice
1 in 6 months; dietitian
provided advice

—

—

1 in 6 months; dietitian
provided advice

—

—

—

—

—

—

7.3 (7.5%)b
8.3 (8.8%)b
0.5 (0.2%)a
7.0 (7.4%)b
8.2 (8.8%)b
1.3 (1.2%)a
10.4 (11.8%)a†
1.3 (1.4%)b†

152/98
146/96
148/59
35/22
34/9

SIB
SIB
PL
SIB
SIB
PL
SIB
PL

162/114
160/105

SIB 20
PL

4.9 (4.9%)a†
0.6 (0.6%)b†

55/40
54/44

SIB 10
PL

7.5 (8.7%)a‡
3.2 (3.8%)b‡

89/60
86/60

SIB 20
PL

4.4 (4.5%)a
0.4 (0.5%)b

15
20
15

James et al. (40)

352/204
115/57

SIB 10–20
PL

McMahon et al. (68)

150/79
74/41

SIB 20
PL

—

�4.4
�0.5

2-Year
weight loss
(kg)

Number of
counseling visits

7 in 6 months; physician
provided minimal
dietary counseling
1 in 6 months
(additional sessions,
as needed); individual
dietary counseling
8 in 6 months;
psychologist provided
tailored advice

8 in 6 months;
—
—
individual dietary
counseling
�11.0§
10.2 (10%)b§ 12 in year 1; total 24 in
� 7.0§
4.7 (4.6%)a§ 2 years; monthly
sessions with a
dietitian with the
option of returning
every 2 weeks
a
4.4 (4.7%) ‡
1 in 6 months; dietary
—
0.5 (0.7%)b‡
advice

Superscripts that differ (a and b) are significantly different ( p � 0.05). Percentage weight loss is provided in parentheses to aid
interpretation.
* Treated by very-low-calorie diet for first month during which participants lost approximately 7.5 kg; data in the table reflect weight losses
from baseline, representing 13 months of treatment.
† Data reflect values from last-observation-carried-forward analysis.
‡ Sibutramine initiated after 2 weeks of a low-calorie diet and a 1.4 kg loss; data reflect weight losses from baseline.
§ Randomization and placebo initiated after 6 months of dieting plus sibutramine, during which patients lost about 11 kg; data in the table
reflect weight loss from baseline.
QD, once daily; SIB, sibutramine; PL, placebo.

Table 2. Randomized double-blind controlled trials of orlistat and lifestyle modification for obesity

Reference

Randomized/
6-Month
completed
Dose
weight loss
(n)
(mg/TID)
(kg)

1-Year
2-Year
weight loss weight loss
(kg)
(kg)

Davidson et al. (70)

657/458
223/133

ORL 120
PL

—

8.7 (8.8%)a
5.8 (5.8%)b

Finer et al. (71)

114/73
114/66
210/14
212/122

ORL 120
PL
ORL 120
PL

�9.0a
�6.6b
—

8.8 (8.8%)a
5.5 (5.5%)a
7.9 (7.9%)a*
4.1 (4.2%)b*

163/139
159/115

ORL 120
PL

(�6.0%)
(�3.5%)

Hauptman et al. (49)

Hollander et al. (69)

James et al. (96)†

23/9
23/11

ORL 120 8.6 (8.4%)
PL
5.5 (5.7%)

Karhunen et al. (86)

45/36
45/36

ORL 120
PL

11.2a
8.7b

Rossner et al. (72)

244/181
243/158

ORL 120
PL

(�8.5%)
(�6.5%)

Sjöström et al. (51)

343/284
340/260

ORL 120
PL

120/97
123//96
1561/1107
1119/722

ORL 120
PL
ORL 120
PL

Van Gaal et al. (97)
Zavoral (98)

—
(9.8%)b
(6.5%)a
—

(6.3%)a
(4.2%)b

(8.4%)
(2.6%)

13.1a
8.6b
9.8 (10.2%)a
4.3 (4.5%)b
10.3 (10.2%)*
6.1 (6.1%)*
—
(9.2%)*
(5.8%)*

Number of
counseling visits

7.6 (7.6%) 18 in 1 year; total 24 in 2
4.0 (4.0%)
years; dietary and exercise
advice; 4 behavioral
modification sessions/year
10 in 6 months; total 16 in 1
—
year; dietary advice
5.1%* 5 in 1 year; total 9 in 2 years;
1.7%*
physician provided brief
dietary and exercise advice;
video-administered
behavioral guidance
9 in 6 months; total 18 in 1
—
year; dietitian provided
dietary and exercise advice;
a minimum of 4 sessions
included behavioral advice
6 in 6 months; total 8 in 1
—
year; dietitian and obesity
nurse provided dietary and
exercise advice
�3 in 6 months; total 4 in 1
—
year; dietitian provided
dietary counseling
(7.8%) 8 in 6 months; total 16 in 2
(4.5%)
years; dietitian provided
dietary and behavioral advice
(�8%)* 16 in 1 year; total 24 in 2
(�4%)* years; dietitian provided
dietary and behavioral advice
14 in 6 months; dietitian
—
provided advice
—
Inconsistent across sites;
nonstandardized instruction
in dietary, exercise, and
behavioral advice

Superscripts that differ (a and b) are significantly different ( p � 0.05). Percentage weight loss is provided in parentheses to aid in
interpretation.
* Data reflect values from last-observation-carried-forward analysis.
†p values were not reported.
TID, three times daily; ORL, orlistat; PL, placebo.

Table 3. Short-term randomized controlled trials evaluating current or former anti-obesity medications and
lifestyle modification

Reference

Randomized/ Number of
completed
counseling
(n)
visits

Treatment groups
1) Lifestyle mod � placebo (PL)
2) Lifestyle mod � med (phentermine)*

Weight
loss (kg)

1) 20/15
2) 20/15

1) 3
2) 3

1) 2.0 (2.0%)a
2) 7.5 (8.3%)b

Brownell and Stunkard (64) 1) Lifestyle mod alone
(at 16 weeks)
2) Lifestyle mod � med (fenflur)†

1) 43/39
2) 69/62

1) 16
2) 16

1) 7.1 (8.0%)a
2) 10.8 (10.9%)b

Craighead (63)
(at 16 weeks)

1) Med alone (fenflur)†
2) Lifestyle mod alone
3) Lifestyle mod � med (fenflur)†

1) 16/13
2) 16/15
3) 14/13

1) 7
2) 16
3) 16

1) 4.8 (6.6%)a
2) 5.7 (7.7%)a
3) 6.9 (8.8%)b

Craighead et al. (62)
(at 26 weeks)

1) Med alone (fenflur)‡
2) Lifestyle mod alone
3) Lifestyle mod � med (fenflur)‡

1) 10/9
2) 40/33
3) 34/31

1) 7
2) 26
3) 26

1) 6.0 (7.3%)a
2) 10.9 (12.0%)b
3) 15.3 (15.6%)c

Wadden et al. (73)
(at 24 weeks)

1) Med alone (SIB)§
2) Lifestyle mod � med (SIB)§
3) Lifestyle mod � LCD � med (SIB)§

1) 19/13
2) 17/13
3) 17/17

1) 7
2) 20
3) 20

1) 5.6 (5.8%)a ¶
2) 11.4 (11.0%)b ¶
3) 17.9 (17.7%)c ¶

Weintraub et al. (65)
(at 34 weeks)

1) Lifestyle mod � PL
2) Lifestyle mod � med (fen-phen)**

1) 54/49
2) 58/54

1) 14
2) 14

1) 4.6 (4.9%)a
2) 14.3 (15.6%)b

Weintraub et al. (99)
(at 24 weeks)

1)
2)
3)
4)

1)
2)
3)
4)

1)
2)
3)
4)

1)
2)
3)
4)

Brightwell and Naylor (66)
(at 8 weeks)

Lifestyle
Lifestyle
Lifestyle
Lifestyle

mod
mod
mod
mod

�
�
�
�

PL
med (phentermine)††
med (fenflur)††
med (fen-phen)††

18/10
20/14
19/8
21/13

3
3
3
3

4.4 (5.0%)a
10.0 (11.0%)b
7.5 (8.4%)b
8.4 (10.1%)b

Superscripts that differ (a, b, and c) are significantly different ( p � 0.05). Percentage weight loss is provided in parentheses to aid in
interpretation.
* Medication dosage was 30 mg/d.
† Medication dosage was up to 160 mg/d.
‡ Medication dosage was up to 120 mg/d.
§ Medication dosage was up to 15 mg/d.
¶ Data reflect values from last-observation-carried-forward analysis.
** Medication dosage was 60 mg/d of phentermine and 15 mg/d of fenfluramine.
†† Medication dosages were: 30 mg/d of phentermine; 60 mg/d of feflurmaine; and 30 mg/d of fenfluramine plus 15 mg/d of phentermine.
Lifestyle mod, lifestyle modification; med, medication; PL, placebo.

results are generalizable to trials of lifestyle modification;
however, the use of a placebo remains a potential
confounder.
In studies of 1- and 2-year durations, sibutramine (10
to 20 mg/d) produced an average weight loss of 7 to 10
kg, which was 5 kg greater than placebo plus lifestyle
modification. Patients maintained 100% of their 6-month
weight losses at 1 year (40,67,68), and 90% of their 1-year
loss at 2 years (40) (Table 1).
More studies have evaluated the long-term effects of
orlistat. In 1-year studies, weight loss averaged 6 to 10 kg,
equal to a 4-kg placebo-subtracted weight loss (49,51,69,72).

In 2-year studies (49,51,70), weight losses averaged 5 to 8
kg, which were also �4 kg greater than placebo. Across
studies, patients maintained nearly 100% of their 6-month
weight loss at 1 year and �75% of this loss at 2 years. The
medication, compared with placebo, reduced the rate of
weight regain but did not prevent it entirely.
In summary, long-term studies of sibutramine and orlistat
demonstrate that the medications significantly improve
long-term weight loss compared with placebo when com
bined with standard monthly or quarterly treatment visits.
However, additional research, particularly with sibutramine,
is needed to assess the long-term efficacy (�2 years) of

these medications. It is also unclear whether medication
would improve results on a more comprehensive behavioral
weight-maintenance program (with biweekly patient visits)
as described by Perri et al. (23).

Does Adding Lifestyle Modification Improve
the Results of Pharmacotherapy?
Clearly, pharmacotherapy improves results of a modest
program of lifestyle modification, but does adding lifestyle
modification improve on the results of pharmacotherapy
alone? This may seem like an inappropriate area of inquiry,
given that pharmacotherapy is only recommended as an
adjunct to a comprehensive lifestyle-modification program.
In clinical practice, however, weight-loss medications are
often used alone.
Earlier studies of formerly approved weight-loss agents
examined the effects of medication alone compared with a
comprehensive program of lifestyle modification and the
combination of the two therapies (62,63). Craighead et al.
(62) found that individuals treated with fenfluramine in
monthly, routine office visits lost an average of 6 kg in 26
weeks; patients treated with weekly group lifestyle modifi
cation alone lost 11 kg. However, patients treated with both
medication and group lifestyle modification lost a signifi
cantly greater amount—15 kg. Thus, the addition of life
style modification improved the results obtained with treat
ment by pharmacotherapy alone (and vice versa). A similar
study (63) of only 16 weeks reached the same conclusions,
although weight losses for all three groups were smaller
than in the 26-week investigation.
Only one study of currently approved medications exam
ined whether adding lifestyle modification improved the
results obtained by medication alone. In a 1-year trial,
Wadden et al. (73) examined the effect of 15 mg/d of
sibutramine combined with three interventions. Patients in
the medication-alone group were instructed to consume a
diet of 1200 to 1500 kcal/d and to walk �150 min/wk;
they were not, however, provided any instruction in be
havior change. Persons in the medication plus lifestylemodification group received the same diet and exercise
prescription but attended weekly group treatment sessions
for the first 5 months and monthly sessions for the remain
der of the year. Patients in a third group received the same
behavioral intervention but for the first 4 months were
prescribed a 1000-kcal/d portion-controlled diet. After 6
months, patients in the medication-alone group lost only
5.8% of initial weight compared with significantly greater
losses of 11.0% and 17.7% for participants in the second
and third groups, respectively. Similar findings were found
at 1-year follow-up. These findings illustrate that lifestyle
modification improves the pharmacological treatment of
obesity. This study, however, did not include a lifestyle-

modification-alone group, which precludes determination of
whether pharmacotherapy improves on comprehensive life
style modification treatment.
Clearly, additional research on sibutramine and orlistat
(as well as agents to be discovered) is needed to determine
whether greater intensity of lifestyle modification improves
the efficacy of these medications, as suggested by the study
by Wadden et al. (73). The use in current placebo-controlled
trials of low-intensity lifestyle programs may simulate prac
tice in a primary-care setting and ensure that any adjunct
behavioral treatment does not mask the effects of the drug.
However, it is possible that the medication’s effects are
enhanced by more aggressive lifestyle interventions.

How Could Combining Medication and
Lifestyle Modification Result in Better
Weight Control than Either
Approach Used Alone?
As reviewed above, weight-loss medications seem to
improve on the effects of low-intensity and possibly com
prehensive lifestyle modification programs. An important
question is how the combination of lifestyle modification
and pharmacotherapy could be more effective than either
approach alone. Three possible ways are discussed.
Additive Hypothesis
First, it is possible that the treatments act additively. Each
treatment may target a unique set of variables, and com
bined, target more variables and result in greater weight
loss. Behavioral treatment teaches patients to control the
external environment. Patients are instructed to control ex
ternal prompts to eat by storing food out of sight, shopping
from a list, avoiding fast-food restaurants, and keeping
records of everything eaten. By contrast, medication would
seem to modify principally biological variables that affect
hunger, fullness, palatability, or fat absorption.
Studies of formerly approved medications support these
hypotheses. Investigations that compared fenfluramine and
lifestyle modification found that patients who received be
havior therapy showed significantly greater improvements
in eating habits, cognitions, and adherence to their eating
schedule (63,74). They also reported greater control of their
weight and felt that the program was more helpful, com
pared with patients treated by fenfluramine alone (63,74).
By contrast, studies of the fenfluramine-phentermine com
bination found that it was associated with greater improve
ments in hunger (65) and evening fullness (65), and with
reduced difficulty with dietary adherence (65), compared
with behavioral treatment alone. The withdrawal of medi
cation also resulted in increased hunger and decreased full
ness (65). These studies suggest that medication and life
style modification targeted different variables.
A recent study of sibutramine reported similar findings
(75). In an 18-week trial, sibutramine (15 mg/d) combined

with intensive lifestyle modification (i.e., weekly group
behavioral treatment) was compared with sibutramine plus
minimal lifestyle intervention (i.e., monthly physician vis
its) and with an intensive lifestyle-modification-alone
group. At the end of treatment, patients treated with sib
utramine plus minimal lifestyle modification reported sig
nificant reductions in hunger and craving but no increases in
their practice of weight-control behaviors (e.g., exercising,
eating vegetables, following a meal plan). By contrast, those
treated with intensive behavior modification alone reported
little change in appetite but significant increases in their
practice of weight-control behaviors. Participants who re
ceived combined treatment (i.e., medication plus behavior
therapy) seemed to reap the benefits of both approaches.
They reported significant improvements in both appetite
and their practice of weight-control behaviors. Based on
these findings, behavioral and pharmacological treatments
seem to target different variables; thus, an additive effect
seems plausible.

Compensatory-Effects Hypothesis
A third possibility is that combination treatment has
compensatory effects. Each treatment may prevent the un
toward effects produced by the other. For example, medi
cation could counteract the declines in resting energy ex
penditure (REE) and leptin that are associated with dieting
and weight loss, and which ultimately slow weight loss. It
might be possible to use medications such as leptin to
reverse the decline in REE that occurs with energy restric
tion and weight loss (79).
Ultimately, additive, synergistic, and/or compensatory
interactions may differ depending on the medication and
lifestyle intervention used and the particular outcome vari
able of interest (e.g., appetite vs. REE). In addition, new
medications are likely to have new mechanisms of action.
Clearly, multiple dimensions of therapeutic efficacy will
need to be considered in evaluating how treatments interact
to enhance weight loss.

Synergistic Hypothesis
A second possibility is that medication and behavioral
treatment act synergistically and enhance one another’s
efficacy. A synergistic effect would occur if the weight loss
produced by combined treatment was greater than the sum
of the weight losses produced from medication therapy and
lifestyle modification alone. This hypothesis is suggested by
examining the placebo-subtracted weight losses (an indica
tion of medication efficacy) in studies of sibutramine. Spe
cifically, in studies that prescribed 15 mg/d of sibutramine,
the most intensive lifestyle-modification program, which
included on-going dietary counseling sessions (43), resulted
in a 9-kg placebo-subtracted weight loss, whereas the two
studies that used less intensive lifestyle-modification ther
apy (76,77) resulted in 7 and 6 kg placebo-subtracted weight
losses, respectively. Thus, the greater intensity of lifestylemodification treatment may have improved the medica
tion’s efficacy. This possibility, however, was only sug
gested; it was not apparent for studies of sibutramine with
10 mg or 20 mg or in studies of orlistat.
There are a number of ways synergistic effects could
occur. For example, behavioral treatment could enhance the
effects of medication by improving medication adherence;
self-monitoring, cue control, and similar behavioral tech
niques could facilitate the behavior of taking medication.
Conversely, by suppressing appetite, anorectic agents could
facilitate adherence to lifestyle modification, including pa
tients’ dietary and possibly exercise compliance. Improved
appetite control could make it easier for patients to adhere to
behavioral goals such as eating a low-calorie, low-fat diet
and recording their food intake. It is also possible that
medication could blunt the palatability and reduce food
value (78), thereby making it easier for patients to adhere to
an appropriate calorie level.

Options for Combining Medication and
Lifestyle Modification
Another important question is when and how best to
combine medication and lifestyle modification to maximize
weight loss and long-term weight control. A stepped care
approach suggests that lifestyle modification should be pre
scribed first, with pharmacotherapy provided only to those
individuals who are unsuccessful, for example, in losing
10% of initial body weight or in improving control over a
risk factor (e.g., type 2 diabetes). Similarly, with a stepped
approach, those who lost 10% would only be prescribed
medication if they began to regain weight (for example, �2
percentage points of their initial loss). Whereas this ap
proach is logical from the standpoints of both safety and
cost, some patients might benefit from receiving both life
style modification and pharmacotherapy from the outset of
treatment. This is particularly true of individuals who re
ported a history of difficulty in losing weight by diet and
exercise alone. Patients with a marked history of weight loss
and regain (i.e., weight cycling) also might wish to begin
taking medication as soon as they reached a weight-loss
plateau (e.g., �1 month). Given the significant weight re
gain that occurs with the withdrawal of either lifestyle
modification or medication, the great majority of patients
will require long-term treatment of some kind. At present,
investigators know little about how best to prescribe life
style modification and medication to maximize both shortand long-term outcomes. There are at least four possible
options, in addition to that of stepped care.
Concurrent Administration
One approach is to introduce both treatments from the
outset and maintain both interventions long-term. Studies
that evaluated this approach typically reduced the frequency

of lifestyle counseling visits after the first 6 to 12 months,
and therefore, did not provide definitive assessments of the
possible benefits of this approach. Investigations with
orlistat found that �60% to 75% of the weight lost during
the first year of treatment was maintained at the end of the
second year (while patients remained on medication), re
sulting in a 5% to 8% weight loss at this time (49,51,70,72).
The one long-term (i.e., 2-year) investigation of sibutramine
that used this approach found that participants maintained
�90% of their maximal weight loss (11%), which was
achieved at 6 months (40).
Similarly, data from formerly approved agents, including
fenfluramine and dexfenfluramine, also revealed beneficial
weight loss effects of simultaneously administering medi
cation and lifestyle modification (80 – 82). Whereas these
data provide support for the concurrent administration of
therapies, some have questioned whether this method is
necessary, particularly when an aggressive dietary interven
tion, such as a very-low-calorie diets (VLCD), is used (83).
Medication is unlikely, for example, to augment weight loss
when prescribed concurrently with a VLCD, but it does
increase costs substantially.
Lifestyle Modification Followed by Pharmacotherapy
A second option is to boost the induction of weight loss
by using the medication after lifestyle treatment has been
initiated. Apfelbaum et al. (67) evaluated the effects of this
approach by adding sibutramine after an initial month of
treatment with a VLCD (providing 200 to 800 kcal/d),
during which patients lost �7.5 kg. Patients who were
subsequently assigned to sibutramine lost an additional 5.2
kg during the ensuing year, whereas those who received a
placebo gained 0.5 kg. These findings suggest that adding
medication after a brief course of VLCD may facilitate
larger weight losses. It is unclear, however, whether the
medication would have induced additional weight loss if
patients had lost 15 to 20 kg by adhering to a VLCD for 2
to 3 months, as these diets are commonly prescribed.
Studies of formerly approved medications also evaluated
the short-term effects of adding pharmacotherapy after life
style modification (63,66). In a study by Craighead (63),
one group received fenfluramine during the second half
(weeks 9 to 16) of a 16-week lifestyle-modification pro
gram; in another group, medication was included only in the
first half (i.e., weeks 1 to 8) of the program. At the end of
the 16 weeks, those who received medication during the
latter half of the program lost 9.3 kg, which was signifi
cantly more than either the behavior therapy alone group
(5.7 kg) or the group that received medication during the
first but not second half of treatment (5.6 kg). Thus, adding
medication during the second 8 weeks of treatment in
creased weight losses by �3.5 kg. In contrast, an earlier
24-week study of phentermine found that starting medica
tion after 8 weeks of placebo and a program of modest

lifestyle modification seemed to benefit only a subgroup of
“slow losers” (66). Further studies are needed to determine
if medication will reliably induce further weight loss in
persons originally treated by lifestyle modification alone.
Medication for Weight Maintenance
Another option is to introduce pharmacotherapy later in
treatment to facilitate the maintenance rather than induction
of weight loss. With this approach, consistent with stepped
care, medication could be introduced at a specific time-point
when the rate of weight loss typically slows (e.g., 6
months), after patients had met a weight-loss criterion (e.g.,
7% to 10% loss), or as a rescue strategy after patients had
regained weight (e.g., 2% or more).
Two studies of orlistat evaluated the effect of adding
medication after a specific period of time. Hill et al. (84)
randomly assigned obese subjects who had lost �8% of
their initial body weight (by diet and exercise alone) to
placebo or orlistat, which was administered for 1 year in
combination with a weight-maintenance diet. At the end of
the year, participants treated with medication regained less
weight than did placebo-treated subjects (32.8% vs. 58.7%
regain of lost weight, respectively). Similarly, Sjöström et
al. (51) randomly assigned patients who lost 5 kg during the
previous year to receive orlistat or placebo during a second
year. During year 2, patients on orlistat lost an additional 0.9
kg, compared with a mean regain of 2.5 kg in patients who
continued on placebo. Overall, these and other (85) studies
suggest that adding medication after treatment by diet and
exercise may minimize weight regain while reducing
the duration of exposure to medication and its potential
side-effects.
Two studies compared the approaches of prescribing
medication to induce weight loss and continuing it for the
long-term vs. using medication for weight maintenance
only. One found that mean weight loss of patients who
received orlistat continuously for 2 years did not differ
significantly from that of patients who began the medication
at year 1 (51). The other study also reported that participants
who began orlistat after 1 year of treatment by lifestyle
modification alone achieved the same weight loss at the end
of 2 years as participants who had received medication for
the entire 2 years (86). It is unclear why later medication
administration resulted in similar weight losses as continu
ous combined treatment. There seems to be a limit to the
total amount of weight loss that is typically produced by
current medications. Patients treated late by pharmacother
apy seem to catch up with those treated early and in whom
weight loss has plateaued.
Intermittent Use of Medication
A final approach is to administer medication and/or life
style modification intermittently. Studies have shown inter

mittent pharmacotherapy to be as (87,88) or almost as
effective (89) as continuous medication. Munro et al. (90),
for example, compared the effects of continuous and inter
mittent treatment with phentermine. One group received
alternating 4-week supplies of active and placebo pills; a
second group received continuous placebo, and the third
received continuous phentermine. After 36 weeks, the al
ternating therapy with phentermine and placebo was as
effective as continued daily treatment with phentermine,
and both were superior to placebo. The authors concluded
that there seemed to be no advantage in taking the medica
tion continuously, because intermittent treatment was as
effective, cheaper, and possibly safer.
Similarly, intermittent therapy was found to be as effec
tive as continuous therapy in a recent study of sibutramine.
Wirth and Krause (88) randomized participants to sibutra
mine administered continuously, sibutramine used intermit
tently with placebo, or placebo given alone for 48 weeks.
All groups received brief dietary counseling from their
physician. After 1 year, there were no significant differ
ences in weight losses between the intermittent vs. contin
uous treatment groups (7.8 kg vs. 7.9 kg, respectively).
In addition, the percentage of patients who experienced
adverse events was similar in all groups. These findings
again suggest that intermittent use of medication could save
costs without sacrificing efficacy.
Weintraub et al. (89) reported findings similar to those of
Munro et al. (90) but came to a different conclusion. In this
study, although the end-of-treatment weight losses were
similar with intermittent and continuous therapies, continu
ous medication (i.e., phentermine and fenfluramine) was
judged preferable to intermittent therapy, primarily because
of the adverse side effects that occurred when medication
was reinitiated. Additional problems included weight gain,
difficulty in adherence, and decreased appetite control dur
ing periods without medication.
In summary, adding medication to boost weight loss
and/or promote weight maintenance may be a more effec
tive and less costly option than prescribing both medication
and lifestyle modification from the outset of treatment.
Whereas it is possible that some patients (e.g., those with a
history of unsuccessful weight-loss attempts or weight cy
cling) would reap more benefit from being offered medica
tion and lifestyle modification concurrently, the effects of
such patient characteristics on treatment outcome need to be
investigated. Further research is also needed to fully assess
the relative benefits of treatments administered intermit
tently or at specific time-points to maximize weight loss and
maintenance. Findings may differ depending on the medi
cation used and its specific side-effect profile. Studies are
also needed to determine whether medications may be used
to prevent weight gain during high-risk periods, including
the winter holidays and times of acute stress.

Potential Pitfalls of Combined Treatments
Some practitioners have voiced concerns that medication
may undermine lifestyle modification (91). For example, if
medication reduces hunger, patients may not be motivated
to practice strategies such as eating at regular intervals or
eating high-fiber foods to prevent hunger and enhance sa
tiety. Failure to practice these behaviors could undermine
weight control in the long-term, particularly if medication
was discontinued or its effects waned over time.
The use of medication may also convey the message that
obesity is “biological” in origin and that personal efforts to
change this “disease” process are futile. Such sentiments
could reduce weight-control self-efficacy and receptiveness
to lifestyle modification, which teaches patients to see them
selves as active participants in solving their problems. Sim
ilarly, medication may foster external attributions for suc
cess. When patients lose weight, they may attribute their
success completely to the medication, and not to their own
efforts, thus further undermining self-efficacy. Conversely,
it is possible that the failure of medication to produce
adequate weight loss could be ascribed to internal causes,
such as inadequate personal self-control. The small but
significant number of medication nonresponders may feel
guilty or hopeless that the medication is not working and
withdraw from weight-management efforts.
Although there is no evidence that, when used together,
medication and lifestyle modification limit one another’s
effectiveness, researchers and practitioners should be sen
sitive to the potential drawbacks of combined therapy.
Investigators also should evaluate potential adverse behav
ioral (e.g., completion of fewer food diaries) and psycho
logical (e.g., decreased self-efficacy, motivation, self-es
teem) effects of combining treatments. Practitioners should
inform patients how the medication and the patient’s own
efforts to modify diet and activity habits potentially com
plement each other to produce a better outcome.

Treatment and Research Implications
Treatment Implications
The data reviewed in this article clearly indicate that
medications, when added to a low-intensity program of
lifestyle modification, improve both the induction and
maintenance of weight loss compared with lifestyle modi
fication alone. Whereas it is likely that combining pharma
cotherapy with more intensive lifestyle modification
will improve results, data with currently approved agents
are lacking.
Research Implications
There are a number of key unresolved issues that require
future research. Foremost is the need for randomized control
trials that include adequate control conditions.

Figure 1: Research design for evaluating the effects of combined
behavioral and pharmacological treatment.

Research Design. The most rigorous test of combination
treatment would require a 2 � 2 design in which minimal
lifestyle modification was administered with placebo and
medication, and intensive lifestyle modification was also
provided with placebo and medication (see Figure 1). These
four groups would provide several comparisons.
First, it is important to measure independent treatment
effects to evaluate the relative contribution of each therapy
to combined treatment. Thus, the model includes groups
that assess whether intensive lifestyle-modification treat
ment is, in fact, more effective than a minimal lifestyle
intervention program (i.e., comparison of cell #2 with cell
#1) and whether medication is, in fact, superior to placebo
(i.e., comparison of cell #3 with cell #1). The comparison of
medication and placebo is relatively straightforward, al
though consideration must be given to the dose of the
medication to be used and whether it may be increased
because of poor response either early or late in treatment. In
addition, the use of placebos that produce side-effects would
also be helpful, as double-blind procedures are often not
maintained in medication trials because therapists and pa
tients can discover a patient’s treatment conditions through
observation of side effects (92).
Selection of the lifestyle interventions presents more
choices. As described previously, intensive lifestyle modi
fication usually consists of 16 to 26 sessions of weekly
group treatment that is provided by a dietitian, psychologist,
or other health practitioner. This approach produces excel
lent weight loss that may be increased further by the use of
a meal replacement (100). Low-intensity lifestyle modifica
tion, by contrast, could take a number of forms, ranging
from 4 to 6 visits a year with a primary-care practitioner
who provided brief diet and exercise counseling to weekly
(or biweekly) visits of 5 to 10 minutes at which patients
were weighed by a medical technician and praised for
keeping food records. (Frequent weigh-ins alone could ac
count for the success of intensive lifestyle modification.)
Investigators may want to design minimal lifestyle interven
tions that can be implemented in primary-care practice.

Protocols used in most industry-sponsored trials have in
cluded relatively few visits, consistent with primary-care
practice.
After the separate effects of medication and lifestyle
intervention have been examined, one of the central ques
tions concerning combined treatment may be addressed:
does adding medication improve on the effects of intensive
lifestyle modification alone? This question is answered by
comparing weight losses and changes in health in the groups
that receive intensive lifestyle modification combined with
placebo (cell #2) vs. medication (cell #4). Results of previ
ous studies lead us to predict that medication plus intensive
lifestyle modification will induce significantly larger weight
losses (and improvements in health) than placebo plus the
same program of lifestyle modification. Perhaps the more
important question is whether the first therapy will be more
effective than the second in maintaining improvements in
weight and health one or more years after weekly group
treatment has been discontinued.
Some have argued that it is inappropriate to test behav
ioral interventions in combination with a placebo (61,91).
Treatment is not administered this way in clinical practice,
and the placebo could undermine the effectiveness of be
havior therapy by not meeting patient’s expectations. The
addition of a fifth treatment cell, intensive lifestyle modifi
cation alone, corrects for this possible shortcoming. If no
differences were consistently found between this treatment
condition and intensive lifestyle modification with placebo,
the fifth cell could be eliminated.
The 2 � 2 design also addresses the question of whether
intensive lifestyle modification improves on the results of
pharmacotherapy. This is revealed by the comparison of
treatment cell # 3 with cell #4. Intensive lifestyle modifi
cation may be required to obtain the best results with most
medications. As noted earlier, Wadden et al. (73) found that
sibutramine plus minimal lifestyle instruction produced a
weight loss less than one-half as large as that resulting from
sibutramine combined with intensive group behavior mod
ification. By contrast, some medications may be so potent
that maximal weight loss may be achieved with only min
imal lifestyle modification, as was suggested by a study of
the fenfluramine-phentermine combination (93).
The relative and combined effects of lifestyle modifica
tion and pharmacotherapy will not be known until studies
similar to those described above are conducted. We note
that the cost of conducting trials that included four or five
treatment conditions could be prohibitive. For studies in
which the efficacy of medication, relative to placebo, has
already been demonstrated, an alternative would be a threegroup design that compared 1) medication plus minimal
lifestyle modification, 2) medication plus intensive lifestyle
modification, and 3) intensive lifestyle modification alone.
The design would address several issues concerning meth
ods of maximizing the benefits of behavioral and pharma

cological interventions. The results of these three-group
designs could inform the design of second-generation stud
ies. Future studies should fully describe the components of
each treatment condition, including the intensity of lifestyle
intervention, the training of individuals who delivered the
therapy (e.g., psychologist, dietitian), and the frequency,
duration, and content of treatment sessions.
Mechanisms of Action. The means by which combined
treatment potentially enhances monotherapy (i.e., pharma
cotherapy or lifestyle modification alone) needs to be de
termined. As a prelude to doing so, it will be important to
better understand the specific variables that are associated
with eating and inactivity, both in the short- and long-term.
For example, it is unclear whether hunger and craving do, in
fact, contribute to overeating and weight gain in most obese
individuals. If found to be the case, investigators would
want to evaluate whether treatments had an effect on these
variables. The effects of medications, as well as behavioral
interventions, on variables including food preoccupation,
macronutrient selection, dietary restraint, hedonic ratings of
food, food preferences, cognitions, and activity level need to
be investigated. Possible effects of medication on optimism
and expectations for success should also be evaluated. Once
independent treatment effects are identified, the ways in
which combined treatments work could be better deter
mined. Obtaining information about treatment mechanisms
is critical for the development of efficient and effective
lifestyle-modification interventions. Depending on the med
ication(s) used, the content of lifestyle-modification treat
ments will likely need to be modified to maximize the
effects of the medication. We have outlined a number
of possibilities to explain the interaction of medication
and lifestyle modification. These mechanisms should be
tested empirically.
Matching Patients to Treatment. Whether various sub
types of obese patients do better with different interventions
has not been studied adequately. Some patients may be
resistant to weight loss with a particular medication and
need more intensive lifestyle treatment or an alternative
medication. The characteristics of treatment responders and
nonresponders need to be clarified more fully. Perhaps
patients in whom emotional complaints override somatic
ones might find behavioral treatment most useful. Patients
who complain of hunger or cravings might find pharma
cotherapy most useful. Other variables such as gender,
body-fat distribution, stress, degree of obesity, age, and
medical conditions need to be evaluated in relation to var
ious treatment outcomes. Research on patient-treatment
matching is needed.
Dissemination. Finally, investigators will need to identify
methods by which combination treatment can be delivered
in an economical and widespread fashion. There are a
number of promising new methods for disseminating be
havioral treatment, including internet-administered inter

ventions (101). Perhaps both medical and behavioral pro
fessionals need to be involved for combination treatment to
be most effective. However, training medical practitioners
and other medical staff to provide brief lifestyle counseling
might be an equally or even more efficient means of pro
viding combination care (93).

Summary and Conclusions
FDA-approved weight-loss medications improve the re
sults of low-intensity programs of lifestyle modification for
weight management. In addition, long-term use of medica
tion facilitates the maintenance of weight loss. At present,
however, investigators know little about how best to com
bine lifestyle modification and medication to maximize
short- and long-term improvements in weight and health.
Research is needed to determine the types of lifestyle inter
ventions that maximize the effects of orlistat and sibutra
mine, as well as of medications to be discovered. Under
standing the optimal means of combining behavioral and
pharmacological therapies is critical to improving the man
agement of obesity in both primary-care practice and in
specialty clinics.
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